Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.

Immunology letters - 15 Feb 2004

Lee Sung-Hyung, Bar-Haim Erez, Goldberger Ofir, Reich-Zeliger Shlomit, Vadai Ezra, Tzehoval Esther, Eisenbach Lea

Abstract excerpt

The effects of Fas-ligand (FasL) expression by tumor cells on their tumorigenicity and immunogenicity have been reported as opposite, contradictory results. In some systems the killing of Fas positive cytotoxic T-cells (CTL) by FasL expressing tumors resulted in increased tumorigenicity while in other systems tumors expressing FasL were eliminated by neutrophil mediated inflammation. In the present study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fas Ligand Protein
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Membrane Glycoproteins

Share to RNA, Messenger

Share to T-Lymphocytes, Cytotoxic

Share to Transfection

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 15019279
DOI: 10.1016/j.imlet.2003.10.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.PMID 15019279Read ↗

Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.Semantic proximity Read ↗

Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy.Semantic proximity Read ↗

CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.Semantic proximity Read ↗

T-cell subset analysis of Lewis lung carcinoma tumor rejection: heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis.Semantic proximity Read ↗

Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.Semantic proximity Read ↗

T-cell subset analysis of 3LL tumor growth.Semantic proximity Read ↗

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.Semantic proximity Read ↗

A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.Semantic proximity Read ↗

Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.Semantic proximity Read ↗

Phenotypic characteristics of lewis lung carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.